- Išparduota
/https://libri-media.knygos-static.lt/f45295d2-0a4b-40cd-9aaf-0bd627787eac/7)
- Autorius: Gerrit Reepmeyer, Maximilian vonZedtwitz, Oliver Gassmann
- Leidėjas: Springer-Verlag GmbH
- Metai: 2008
- ISBN: 9783540776369
- ISBN-10: 3540776362
- ISBN-13: 9783540776369
- Formatas: PDF
- Kalba: Anglų
Leading Pharmaceutical Innovation (el. knyga) (skaityta knyga) | knygos.lt
Atsiliepimai
Formatai:
Aprašymas
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
Elektroninė knyga:
Atsiuntimas po užsakymo akimirksniu! Skirta skaitymui tik kompiuteryje, planšetėje ar kitame elektroniniame įrenginyje.
Mažiausia kaina per 30 dienų: 121,89 €
Mažiausia kaina užfiksuota: Kaina nesikeitė
- Autorius: Gerrit Reepmeyer, Maximilian vonZedtwitz, Oliver Gassmann
- Leidėjas: Springer-Verlag GmbH
- Metai: 2008
- ISBN: 9783540776369
- ISBN-10: 3540776362
- ISBN-13: 9783540776369
- Formatas: PDF
- Kalba: Anglų
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
Atsiliepimai